Biotechnology · Wilmette, Illinois, United States
$104.94
+5.95% (+$5.89)2026-07-09
Smart-Money SignalNeutral · 43/100— Insiders are net sellers over 90 days (-$639K, 6 sales vs 4 buys)
Revenue$0
Net Income-$3.9M
Market Cap$703.0M
Price Performance
Historical data including institutional events
Company Profile
C
Chandler Robinson
CEO & Executive Director
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- Founded
- 2014
- Employees
- 16
- Headquarters
- Wilmette, Illinois, United States
- Website
- www.monopartx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...